Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab

Authors

  • Shoko Miyamoto Hyogo college of medicine
  • Yasutomo Imai Department of Dermatology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
  • Masaru Natsuaki
  • Kiyofumi Yamanishi
  • Nobuo Kanazawa

DOI:

https://doi.org/10.2340/actadv.v102.295

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int 2020; 69: 356-369.

https://doi.org/10.1016/j.alit.2020.02.006

de Wijs LEM, Fujimoto RFT, Andrinopoulou ER, Nijsten T, Hijnen D, Kataoka Y. Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures. Br J Dermatol 2021; 185: 555-562.

https://doi.org/10.1111/bjd.19897

Treister AD, Lio PA. Remittive effect of dupilumab in atopic dermatitis. Dermatol Ther 2018; 31: e12711.

https://doi.org/10.1111/dth.12711

Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis a randomized clinical trial. JAMA Dermatol 2020; 156: 131-143.

https://doi.org/10.1001/jamadermatol.2019.3617

Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132: 106-112.

https://doi.org/10.1111/j.1365-2133.1995.tb08633.x

Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021; 126: 40-45.

https://doi.org/10.1016/j.anai.2020.07.026

Kovalenko P, Davis JD, Li M, Rippley R, Ardeleanu M, Shumel B, et al. Base and covariate population pharmacokinetic analyses of dupilumab using Phase 3 data. Clin Pharmacol Drug Dev 2020; 9: 756-767.

https://doi.org/10.1002/cpdd.780

Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid 2018; 13: 13-20.

https://doi.org/10.2147/CE.S133661

Imai Y, Kusakabe M, Nagai M, Yasuda K, Yamanishi K. Dupilumab effects on innate lymphoid cell and helper T cell populations in patients with atopic dermatitis. JID Innov 2021; 1: 100003.

https://doi.org/10.1016/j.xjidi.2021.100003

Downloads

Published

2022-06-09

How to Cite

Miyamoto, S., Imai, Y., Natsuaki, M. ., Yamanishi, K. ., & Kanazawa, N. (2022). Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab. Acta Dermato-Venereologica, 102, adv00731. https://doi.org/10.2340/actadv.v102.295

Issue

Section

Short Communication

Categories